de Isidro-Gómez et al: “Facilitating the identification of cryo-EM hit matter in drug discovery with Astex-Faro”, bioRxiv. 2026

de Isidro-Gómez et al: “Facilitating the identification of cryo-EM hit matter in drug discovery with Astex-Faro”, bioRxiv. 2026

https://doi.org/10.64898/2026.11.03.763890

O’Brien et al; “IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer”; Radiother Oncol 2026

O’Brien et al; “IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer”; Radiother Oncol 2026

https://doi.org/10.1016/j.radonc.2026.111832

Tiu et al; “IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial”; Nature Communications, 2026

Tiu et al; “IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial”; Nature Communications, 2026

https://www.nature.com/articles/s41467-026-77552-7

 

 

del Pozo et al: “Discovery of Novel Oral Covalent Inhibitors Targeting Active GTP-Bound KRASG12C with Potent Antitumor Activity”, J. Med Chem. 2026

del Pozo et al: “Discovery of Novel Oral Covalent Inhibitors Targeting Active GTP-Bound KRASG12C with Potent Antitumor Activity”, J. Med Chem. 2026

https://doi.org/10.1021/acs.jmedchem.6c01318

 

 

Gao et al: “Altered Inflammatory Signature in a C9ORF72 -ALS iPSC-Derived Motor Neuron and Microglia Coculture Model”, Glia. 2026

Gao et al: “Altered Inflammatory Signature in a C9ORF72 -ALS iPSC-Derived Motor Neuron and Microglia Coculture Model”, Glia. 2026

https://doi.org/10.1002/glia.70084

 

 

Sheth et al: “Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays”, Clin Chem Lab Med. 2026

Sheth et al: “Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays”, Clin Chem Lab Med. 2025/2026

https://doi.org/10.1515/cclm-2025-0610

 

 

Callahan, et al: “The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein-Protein Interaction for the Treatment of COPD”, J Med Chem. 2026

Callahan, et al: “The Discovery of GSK3227634: A Potent Inhaled Inhibitor of the KEAP1/NRF2 Protein-Protein Interaction for the Treatment of COPD”, J. Med Chem. 2026

https://pubs.acs.org/jmcmar/article/69/17/20859/5256079/The-Discovery-of-GSK3227634-A-Potent-Inhaled

 

 

2026 AACR (poster): Enabling fragment-based drug discovery for direct small molecule inhibition of MYC

View Poster:
2026 AACR (poster): Enabling fragment-based drug discovery for direct small molecule inhibition of MYC

 

 

Ma et al: “From KRASG12D to Pan-KRAS Inhibitors ─ A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design”, J. Med Chem. 2026

Ma et al: “From KRASG12D to Pan-KRAS Inhibitors ─ A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design”, J. Med Chem. 2026

https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c03662

 

 

AD/PD 2026 (poster): Drug Discovery Application of Complex Human iPSC-Derived Models of Neurodegeneration and Neuroinflammation

View Poster:
AD/PD 2026 (poster): Drug Discovery Application of Complex Human iPSC-Derived Models of Neurodegeneration and Neuroinflammation